Savolitinib with osimertinib for treating EGFR- mutated, MET-overexpressed advanced non-small-cell lung cancer

Savolitinib in combination with osimertinib is in clinical development for treatment of acquired mesenchymal epithelial transition factor (MET)-mediated osimertinib resistance in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancers in the UK and at the metastatic stage, the disease has already spread from the lungs to other sites. EGFR is a protein found on cells, which helps them grow. Changes (mutations) in the EGFR gene results in the uncontrolled cell growth in cancerous cells. MET overexpression can also lead to tumour growth and metastatic progression.